Nonalcoholic steatohepatitis (NASH), which is the most severe histological form of nonalcoholic fatty liver disease, is emerging as the most common clinically important form of liver disease in developed countries. Although its prevalence is 3% in the general population, this increases to 20-40% in obese patients. Since NASH is associated with obesity, its prevalence has been predicted to increase along with the growing epidemic of obesity and type 2 diabetes mellitus. The importance of this observation comes from the fact that NASH is a progressive fibrotic disease in which cirrhosis and liver-related death occur in 25 and 10% in these patients, respectively, over a 10-year period. This is of particular concern given the increasing recognition of NASH in the developing world. Treatment consists of treating obesity and its comorbidities: diabetes and hyperlipidemia. Nascent studies suggest that a number of pharmacological therapies may be effective, but all remain unproven at present. Histological and laboratory improvement occurs with a 10% decrease in bodyweight. Bariatric surgery is indicated in selected patients. A greater understanding of the pathophysiological progression of NASH in obese patients must be obtained in order to develop more focused and improved therapy.
Introduction
In the United States, over the last quarter century, there has been an obesity epidemic which has yet to plateau. Dietary modification and sedentary lifestyle have been identified as key perpetuates. The prevalence of the metabolic (insulin resistance) syndrome and its sequelae (e.g. type 2 diabetes mellitus, cardiovascular disease, nonalcoholic fatty liver disease) have increased in parallel fashion [1] [2] [3] . Similar trends are now being discovered worldwide in populations which have undergone migration and urbanization. We are just now beginning to realize the devastating effect these trends may have in terms of future health risk.
Obesity
From 1960 to 2000 in the United States the prevalence of obesity (BMI ≥30) for adults aged 20-74 years has increased from 13.4 to 30.9% [4] (table 1) . The prevalence of obesity was relatively constant from 1960 to 1980, then increased by 8.3% from 1980 to 1990 and 7.6% from 1990 to 2000. Likewise, the prevalence of overweight (BMI for age ≥95th percentile) among children in the United States increased in similar fashion from 1960 to 2000, culminating in a prevalence of 10% for 2-to 5-year-olds and 15% for 6-to 19-year-olds [5] (table 2) .
Similar trends have been seen in migrant populations which are likely due to the adoption of 'Westernized' dietary and lifestyle habits. The prevalence of overweight Mexican-Americans increased 30.9-39.1% in men and 41.5-48.1% in women from approximately 1984 to 1990 [6] . A cross-sectional study in people of African origin showed a stepwise increase in the prevalence of obesity from Nigeria (5.4%) to Jamaica (23.2%) to the United States (39.0%), following the approximate path of migration [7] . Likewise, migrant Asian Indians tend to have higher BMI than those of urban-or rural-based sedentees in India [8] . Furthermore, Tokelauans who migrated to New Zealand because of a natural disaster increased their BMI levels from 24.1 to 28.7 between 1968 and 1982, while BMI levels in non-migrants only increased from 24.8 to 26.1 [9] .
Urbanization of developing countries has shown trends in obesity similar to that of the United States. The prevalence of obesity from 1975 to 2003 among adult Brazilian men aged ≥20 years increased from 2.7 to 8.8%, and in Brazilian women it increased from 7.4 to 13%, reflecting a prevalence rate which almost doubled in both genders over a 28-year period [10] . Likewise, the prevalence of overweight and obesity increased 2.0-5.2% from 1992 to 2002 among Vietnamese adults, affecting urban residents more than their rural counterparts [11] . These trends hold true for adolescents as well as adults. The prevalence of overweight in young persons aged 6-18 years increased 4.1-13.9% in Brazil (from 1975 to 1997), 6.4-7.7% in China (from 1991 to 1997), and 15.4-25.6% in the United States (from 1974 to 1994) [12] .
Using Western Criteria for Defining Obesity
Using Western criteria for defining obesity (BMI >30), less than 5% of South Asians and Asian Pacific populations will be defined as obese. However, obesity-related metabolic disorders occur at lower BMI levels in Asians. Data from South Asia, Singapore and Hong Kong demonstrate that in those native populations, the clustering of metabolic risk factors begins to increase at BMI of approximately 23. Therefore the recommended BMI cutoff values for 
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Values are expressed as percentages with standard error in parentheses. 1 Weight for length at the 95th percentile or higher is considered overweight.
overweight for Asians are from 23-25 and for obesity more than 25, according to the new WHO guidelines. Applying these new criteria, the prevalence of obesity in Asian populations is significant (table 3) . There are also emerging data that the numbers will worsen with the increasing adoption of a Western lifestyle.
Metabolic (Insulin Resistance) Syndrome
Components of the metabolic syndrome include central obesity (waist circumference ≥102 cm in men, ≥88 cm in women), hypertriglyceridemia (serum triglycerides ≥150 mg•dl -1 ), low HDL cholesterol (<40 mg•dl -1 in men, <50 mg•dl -1 in women), hypertension (blood pressure ≥130/85 mm Hg), and hyperglycemia (fasting glucose ≥100 mg•dl -1 ) [13, 14] . At least three of the above criteria are necessary to be labeled as having metabolic syndrome [13] .
The prevalence of the metabolic syndrome among US adults aged ≥20 years increased from 28% (or ~50 million people) in 1990 to 31.9% (or ~64 million people) in 2000, a relative change of 13.8% [15] (table 4) . The prevalence of the metabolic syndrome in US adolescents aged 12-19 years in 2000 was 9.4% (or 2.9 million people); the prevalence in obese adolescents was 44.2% (table 5) , which underscores the importance of adiposity in the development of insulin resistance and the metabolic syndrome [16] .
Of particular interest is South Asia where abdominal obesity is common and evident even in non-obese people. The prevalence of the metabolic syndrome in South Asian populations ranges from 11 to 41% depending on the region of India, and South Asians have an unusually high tendency to develop type 2 diabetes mellitus and coronary heart disease [17] [18] [19] . Even though the prevalence of the metabolic syndrome in Asian Indian adolescents is low, the prevalence of insulin resistance remains high (27%) [20, 21] . 
Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of disease ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), which carries a risk of progression to cirrhosis and end-stage liver disease [22, 23] . NAFLD is considered the hepatic manifestation of the metabolic (insulin resistance) syndrome and its prevalence has paralleled the rise in obesity such that NAFLD is currently the most common chronic liver disease in the United States [24] [25] [26] .
The prevalence of hepatic steatosis in a probability-based population from Dallas, Tex., was 31%; the prevalences per ethnic group were: Whites (33%), Blacks (24%), and Hispanics (45%) [25] . The prevalence of the metabolic syndrome in an unselected cohort of subjects with NASH was found to be 87%; when NASH subjects with type 2 diabetes mellitus were excluded, the prevalence remained higher than the general population at 38% [27, 28] .
Nearly 25% of the urban population of India has NAFLD [19] and therefore may be at risk of developing the same clinical sequelae that has been described in other populations. It should be emphasized that NASH should be considered as the most severe form of a larger spectrum of NAFLD with histologic findings ranging from fat alone, to fat plus inflammation, to fat plus hepatocyte injury (ballooning degeneration) with or without fibrosis, polymorphonuclear cells or Mallory hyaline. Only fat plus hepatocyte injury with or without fibrosis should be considered NASH. The significance of these histologic categories rests not only on the fact that the prevalence varies by histology, with steatosis alone with or without inflammation being more common than NASH, but that clinical outcomes also vary by histologic category. Therefore, it is important to reliably distinguish NASH from other histologic types of NAFLD. Cirrhosis develops in 15-25% of NASH patients [29] , and once developed, 40% of these patients may experience a liver-related death over a 10-year period, with mortality rates similar to or worse than cirrhosis associated with 1 At least one controlled trial in humans has been performed. 2 Uncontrolled trial in humans has been performed. 3 Used only in animal models thus far. 4 Not effective. The only controlled trials (vitamin E, vitamin C, or ursodeoxycholic diet) were no better than controls.
hepatitis C. NASH is also now considered the major cause of cryptogenic cirrhosis. NASH-associated cirrhosis can also decompensate into acute liver failure, progress to hepatocellular carcinoma, and recur after transplantation.
In contrast, steatosis alone is reported to have a more benign clinical course, although progression of fibrosis in cirrhosis has occurred in 3% of those patients with steatosis alone.
Pathophysiological Treatment
There are many potential pathophysiological factors that, either alone or in combination, may provide the basis for effective therapy that has yet to be established. Table 6 lists each of the proposed pathophysiologic factors and the potential therapies. Further proof-of-principle studies are required to determine the optimal therapeutic strategies for NAFLD that may vary among different populations.
Discussion
Dr. Mathur: Could you enlighten us more on lean NASH and how does it develop [1] ? Secondly, as a hepatologist, what clinical and public health advice would you give for tackling simple steatosis?
Dr. McCullough: The majority of people with lean NASH or fatty liver are really not lean; there is increased visceral fat in the majority of those patients. As opposed to the US, in the majority of cases the appropriate BMI in developing countries is much less. There are clear cases of high triglycerides by themselves increasing fatty liver. On the second question regarding the impact on healthcare of simple steatosis, I think this only pertains to very selective groups of patients. We are now increasingly using liver donors, and because 30% of America is fat, if the donors have steatosis, those livers can't be used. Fatty liver disease also adversely affects the progression of hepatitis C, and people with fatty liver disease have a much higher progression to cirrhosis. The 3rd point is that, although this is not as clear as the first two that I just mentioned, it is likely that these livers are more sensitive to drugs and it is also becoming with a little more certain that they are more sensitive to anesthesia. But steatosis itself in the progression of cirrhosis is not a bad thing (2%), but what it does to chronic inflammation, I don't know.
Dr. Giovannini:
Alcoholism is very interesting because there is a big difference when we speak only about beer, but if we speak about wine types it must be remembered that there is a difference between red and white wine. Are obese people protected from NAFLD? To what extent may hepatic metabolism influence brain activity?
Dr. McCullough: The association with red wine is probably the strongest. Pinot noir has the highest concentration of resorbitol. I really don't know what effect it has on the brain. We know that the canabinoid receptors are activated in the brain, but obesity and the brain is not my field of expertise. I really don't know if obese people are protected from NAFLD. Actually some of the best data have come from Northern Italy. It is the same as in the United States, only 30% of people have increased fat. But those studies were done with ultrasounds. About 30% of the liver must be replaced by fat tissue. Mass spectroscopy can pick up 5%, and 5% of fat is normal if metabolic processes are being studied. I really don't know the answer to that question.
Dr. Giovannini: The problem in Asian and African countries is alcohol dehydrogenase deficiency. Perhaps Caucasians have more alcohol dehydrogenase enzymatic activity, and some problems have arisen with a lower alcohol dehydrogenase activity.
Dr. McCullough: That is somewhat different. If everyone here drank 60 g alcohol/ day, we would all get fatty liver; that's not a question, that's a dose effect. The pathways of fat in the liver are completely different, and the enzyme pathway is something that probably has not been considered. The pathways that are activated in fatty liver disease are lysosomes, mitochondria and peroxisomes.
Dr. Kayal: In children with fatty liver, what would be the least invasive and least expensive way to monitor them for their fat content in the liver?
Dr. McCullough: In United States the prevalence is not as clear as in adults, but in pediatrics the best data come from San Diego. About 19% have fatty liver disease and there is a report of early cirrhosis developing in a 5-year-old from this disease. There is a statement, but without much data that I am aware of, that in the average United States high school about 2-3 children will have cirrhosis. Monitoring is a problem. People and parents in particular don't want to have their children biopsied. In the NASH study we had a pediatric population and a lot of trouble recruiting children because we only put children with NASH on a treatment protocol. So the answer to that also is not known, but I did not discuss alternate ways of diagnosing NASH other than apoptosis. Function tests are coming that will look at the activation of lysosomes and mitochondria perhaps. What we need are good noninvasive methods, if they are functional or static tests that give us a reliability of probably 85%, that will be acceptable. But this epidemic is coming to the pediatricians. I have a metabolic clinic and I am frequently seeing 20-year-olds with cirrhosis from this disease.
Dr. Sesikaran: M30 is a noninvasive marker and is expressed in many other apoptotic cells as well. We have studied intestinal epithelial cells, even when they undergo apoptosis they express M30. How could it be specific to liver cell apoptosis because when there is oxidative stress many other cells in the body also undergo apoptosis?
Dr. McCullough: I look forward to that data because this is specific for cytocarotene-18; so that is predominantly in the liver. Initially these were our own data, but they have been reproduced now by 2 other laboratories.
Dr. Sesikaran: We used M30 in the in situ tissue kit, and this was demonstrated in intestinal cells undergoing apoptosis [2] .
Dr. Jaigirdar: In pediatrics, especially in enterology, we treated a fatty acid oxidation disorder with L-carnitine. I would like to ask about NASH and L-carnitine?
Dr. McCullough: The evidence shows that there is no trouble with mitochondrial oxidation in this disease.
Dr. Popkin: This is a slightly different but related issue. From my understanding we have fatty liver that may be benign not inflamed, not damaged, and then we have fatty liver disease, which is a tiny subset of everybody with fatty liver. Clearly in the US and in many countries we have enormous amounts of fatty liver. If we are studying the metabolic syndrome and find someone has 4 or 5 of the various symptoms at a high level, forgetting about whether there is a syndrome or not, do we need to study your ELISA and will it really add anything to what we know from a diagnostic side?
Dr. McCullough: I did not show these data, but it is clear that the more the components of the metabolic syndrome, the more likely that you have fatty liver disease. If you have 3, you have an about 45 or 50% chance of having fatty liver disease.
Dr. Popkin: So there is enough variability that one would gain in diagnostics by testing for fatty liver disease independently. The question is does your ELISA separate between fatty liver and fatty liver disease at enough specificity?
Dr. McCullough: This test has not yet been marketed and I am not suggesting that it be used as a diagnostic test; I was simply using it as an example of what we need to make the separation between good and bad fat in a noninvasive fashion. There are a number of different discriminative functions out there that I chose not to discuss because they are worse than that. What I am usually asked by hepatologists is, should we screen? The answer is probably not yet because we don't have a treatment. Once we have safe treatment then that question becomes somewhat moot because then we have to separate good fat from bad fat, and a noninvasive test with even an 85% predictability will probably be cost-effective.
Dr. Matthai: What is the effect of lipid-lowering agents on the progression of NAFLD? Do they play any role at all?
Dr. McCullough: That is a very good question. Clofibrate didn't work, but there are some data that gemfibrozil decreases ALT. The usual problem is that people say that it is not safe to use those drugs. But they are absolutely safe to use, there is no contraindication.
Dr. Kalhan: For a variety of reasons there is a large burden of background inflammation. What is the impact of this background inflammation on obesity, NAFLD and all the comorbidities?
Dr. McCullough: Inflammation is absolutely present in NAFLD. T cells are important. If the inflammation is suppressed by suppressing macrophage activity, just as in alcoholic liver disease, NAFLD in certain animal models gets better. So chronic inflammation is a very important component of liver disease.
Dr. Kalhan: My question was more in relation to other chronic inflammations in the body. In the organism or human being living in a developing country with a large burden of parasites or whatever, if you measure their circulating cytokines they are probably higher than in the Western societies. Does obesity have a different form in these people? Does liver disease worsen in these types of people? Are there any data?
Dr. McCullough: I am not aware of any data in terms of the ratio of good fat to bad fat in developing countries. The data I showed on prevalence are just based on ultrasounds.
Dr. Yajnik: We have a study, called the Coronary Risk of Insulin Sensitivity in Indians (CRISIS). We measured body fat by different techniques in 150 men from rural areas, 150 from urban slums, and 150 middle income patients. We found progressive increases in body adiposity, liver fat (measured by CT), and abdominal fat volume measured by MRI. We also measured a number of inflammatory markers. CRP levels were highest in the urban middle class, while total leukocyte count, IL-6 and TNF-a were highest in slum dwellers, suggesting a contribution from the infective environment. We found that hyperglycemia and insulin resistance in the urban middle class were substantially enhanced by their adiposity [3] . We are looking at other markers. Dr. McCullough: Depending on the type of fat I think it is probably fine; the oceanic societies eat a lot of n-3, and they do fine.
Dr. Arora: What is the difference in fat accumulation due to obesity and that due to severe malnutrition in the liver?
Dr. McCullough: With severe malnutrition you get fatty liver disease and the problem is you don't have enough export proteins of the triglycerides. Whether that is an inflammatory state or not, I don't know.
Dr. Sesikaran: We always believed that fatty liver with undernutrition never leads to cirrhosis unless it coexists with hepatitis B. Yet there is a situation in which a fatty liver could lead to cirrhosis. So the fat accumulation in the liver due to undernutrition and that associated with excess adiposity obviously seem to have a different etiopathologies.
Dr. McCullough: Did you say that malnutrition in fatty liver disease can progress to cirrhosis?
Dr. Sesikaran: It can, but it does not unless there is a coexistent hepatitis B. Dr. McCullough: I am pretty sure that the mechanism for fatty liver disease in that condition is failure to export protein. I assume that it is not an inflammatory state, but I have never looked at liver tissue from that type of patient, so I don't know.
Dr. Ganapathy: I was just wondering whether, in a state of type 2 diabetes, by the time it is manifest the patient has already gone through a phase with an altered immune status. Gut-associated lymphoid tissue is the biggest system, and endotoxins, lipopolysaccharides, translocation of organisms, they all get into the liver. Kupffer cells can be altered with altered cytokine profile in the liver, and we have seen this in neonates who have sepsis with jaundice and negative blood cultures. So could this be a contributing factor to NASH and could we do something at the gut level to prevent this from happening?
Dr. McCullough: There are some very preliminary studies looking at probiotics that help to decrease endotoxin. The thought is that in obesity there is a leaky gut, and there is some information about that which would suggest measuring endotoxin, and then induce macrophages by TL4 or CD38 or those receptors, and I think it is a reasonable hypothesis to test. I myself am not a big probiotic fan because there have been some deaths described in the United States mostly in inflammatory bowel disease. I like prebiotics, fibers that type of thing, but I think it is a very reasonable hypothesis in this disease because a lot of this disease very closely mimics alcoholic liver disease, and that disease is largely mediated by endotoxin, gut endotoxin in active drinkers. I think you are probably right.
